Prominent bradycardia in a COVID-19 patient receiving Remdesivir: a case report

Sidhi Laksono Purwowiyoto (1), Grace Trifena Hosea (2)
(1) Fakultas Kedokteran Universitas Muhammadiyah Prof Dr Hamka, Indonesia,
(2)

Abstract

Remdesivir is a commonly used antiviral drug to treat COVID-19. Remdesivir has some side effects; however, whether it has any effect on cardiac is rarely reported. A 44-year-old woman with symptomatic confirmed COVID-19 was treated with intravenous remdesivir 200 mg on day one and followed with 100 mg remdesivir until day five. Three days after the treatment, she had significant bradycardia shown on the electrocardiography; however, the patient had no complaint or symptom regarding the bradycardia. Based on the discussion with the cardiology team, it was decided to cease remdesivir and replace it with oseltamivir, and the ECG showed some improvement. Remdesivir is a drug that should be used safely and cannot be taken at home, as there may be side effects left unaware. 

Full text article

Generated from XML file

References

Hafeez Y, Grossman SA. Sinus Bradycardia. 2021. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.

FDA Approves First Treatment for COVID-19 [Internet]. fda.gov. 2021 [cited 11 July 2021]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19

Brown A, Won J, Graham R, Dinnon K, Sims A, Feng J et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Research. 2019; 169:104541.

Fan Q, Zhang B, Ma J, Zhang S. Safety profile of the antiviral drug remdesivir: An update. Biomedicine & Pharmacotherapy. 2020; 130:110532.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine. 2020;382(24):2327-2336.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395(10236):1569-1578.

Sanchez-Codez M, Rodriguez-Gonzalez M, Gutierrez-Rosa I. Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection. European Journal of Pediatrics. 2021;180(5):1627-1627.

Gubitosa J, Kakar P, Gerula C, Nossa H, Finkel D, Wong K et al. Marked Sinus Bradycardia Associated with Remdesivir in COVID-19. JACC: Case Reports. 2020;2(14):2260-2264.

Gupta A, Parker B, Priyadarshi V, Parker J. Cardiac Adverse Events with Remdesivir in COVID-19 Infection. Cureus. 2020;12: e11132.

Day L, Abdel-Qadir H, Fralick M. Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man. Canadian Medical Association Journal. 2021;193(17): E612-E615.

Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Current Emergency and Hospital Medicine Reports. 2013;1(2):83-97.

Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A et al. Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine. 2020;383(19):1813-1826.

Pan H, Peto R, Karim Q, Alejandria M, Henao-Restrepo A, García C et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. N Engl J Med. 2021; 384:497-511

National Institutes of Health. Therapeutic Management of Hospitalized Adults With COVID-19 [Internet]. covid19treatmentguidelines. 2021 [cited 14 July 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/

WHO recommends against the use of remdesivir in COVID-19 patients [Internet]. Who.int. 2021 [cited 14 July 2021]. Available from: https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients

Pelleg A, Belhassen B. The mechanism of the negative chronotropic and dromotropic actions of adenosine 5′-triphosphate in the heart: an update. J Cardiovasc Pharmacol 2010;56:106–9.

Authors

Sidhi Laksono Purwowiyoto
sidhilaksono@uhamka.ac.id (Primary Contact)
Grace Trifena Hosea
Author Biography

Sidhi Laksono Purwowiyoto, Fakultas Kedokteran Universitas Muhammadiyah Prof Dr Hamka

Kepala Laboratorium Kateterisasi Jantung KSM Jantung RSUD Pasar Rebo, Jakarta Timur

Purwowiyoto, S. L., & Hosea, G. T. (2022). Prominent bradycardia in a COVID-19 patient receiving Remdesivir: a case report. Qanun Medika - Medical Journal Faculty of Medicine Muhammadiyah Surabaya, 6(2). https://doi.org/10.30651/jqm.v6i2.9379

Article Details

Medical education in clerkship: From here and out

Bintang Arroyantri Prananjaya, Zain Budi Syulthoni, Ziske Maritska, Lathifah Nudhar, Syarifah...
Abstract View : 32
Download :14

The anxiety level of pregnant women at Siti Khodijah Muhammadiyah Sepanjang Hospital during COVID-19 pandemic

Ninuk Dwi Ariningtyas, Aulia Nuril Islamy, Roni Subagyo, Muhammad Anas
Abstract View : 17
Download :8

Community perception and experience of health services in the midst of an earthquake and COVID-19 pandemic: A phenomenological study

Gadis Meinar Sari, Amrina Rosyada, David Nugraha, Farida Fitriana, Alifina Izza, Silvia Maya Ananta
Abstract View : 25
Download :11

An overview of anxiety levels of Muhammadiyah citizens against COVID-19 vaccination in Surabaya

Siti Aisyah, Ira Purnamasari, Uswatun Hasanah, Dede Nasrullah, Vika Ramadhana Fitriyani
Abstract View : 431
Download :112